These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 14597947

  • 1. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
    Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A.
    Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
    [Abstract] [Full Text] [Related]

  • 2. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
    Belardinelli R, Cianci G, Gigli M, Mazzanti M, Lacalaprice F.
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
    [Abstract] [Full Text] [Related]

  • 3. Trimetazidine potentiates the effects of exercise training in patients with ischemic cardiomyopathy referred for cardiac rehabilitation.
    Belardinelli R, Lacalaprice F, Faccenda E, Volpe L.
    Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):533-40. PubMed ID: 18797405
    [Abstract] [Full Text] [Related]

  • 4. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
    Marazzi G, Wajngarten M, Vitale C, Patrizi R, Pelliccia F, Gebara O, Pierri H, Ramires JA, Volterrani M, Fini M, Rosano GM.
    Int J Cardiol; 2007 Aug 09; 120(1):79-84. PubMed ID: 17134770
    [Abstract] [Full Text] [Related]

  • 5. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
    Monti LD, Setola E, Fragasso G, Camisasca RP, Lucotti P, Galluccio E, Origgi A, Margonato A, Piatti P.
    Am J Physiol Endocrinol Metab; 2006 Jan 09; 290(1):E54-E59. PubMed ID: 16174656
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
    Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A.
    Am Heart J; 2007 Sep 09; 154(3):602.e1-5. PubMed ID: 17719313
    [Abstract] [Full Text] [Related]

  • 7. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A.
    J Am Coll Cardiol; 2006 Sep 05; 48(5):992-8. PubMed ID: 16949492
    [Abstract] [Full Text] [Related]

  • 8. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy.
    Marazzi G, Gebara O, Vitale C, Caminiti G, Wajngarten M, Volterrani M, Ramires JA, Rosano G, Fini M.
    Adv Ther; 2009 Apr 05; 26(4):455-61. PubMed ID: 19396409
    [Abstract] [Full Text] [Related]

  • 9. The effects of trimetazidine on heart rate variability in patients with slow coronary artery flow.
    Topal E, Ozdemir R, Barutcu I, Aksoy Y, Sincer I, Akturk E, Cehreli S.
    J Electrocardiol; 2006 Apr 05; 39(2):211-8. PubMed ID: 16580422
    [Abstract] [Full Text] [Related]

  • 10. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.
    Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GM.
    Eur Heart J; 2004 Oct 05; 25(20):1814-21. PubMed ID: 15474696
    [Abstract] [Full Text] [Related]

  • 11. [Value of trimetazidine in the long-term treatment of cardiomyopathies of ischemic origin].
    Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H.
    Ann Cardiol Angeiol (Paris); 1989 Mar 05; 38(3):179-82. PubMed ID: 2735733
    [Abstract] [Full Text] [Related]

  • 12. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.
    Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M.
    Cardiovasc Diabetol; 2003 Nov 28; 2():16. PubMed ID: 14641923
    [Abstract] [Full Text] [Related]

  • 13. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.
    Schwartz SL, Ratner RE, Kim DD, Qu Y, Fechner LL, Lenox SM, Holcombe JH.
    Clin Ther; 2008 May 28; 30(5):858-67. PubMed ID: 18555933
    [Abstract] [Full Text] [Related]

  • 14. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A.
    Eur Heart J; 2006 Apr 28; 27(8):942-8. PubMed ID: 16510466
    [Abstract] [Full Text] [Related]

  • 15. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.
    Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A.
    J Cardiovasc Pharmacol; 2007 Nov 28; 50(5):585-9. PubMed ID: 18030070
    [Abstract] [Full Text] [Related]

  • 16. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
    Tuunanen H, Engblom E, Naum A, Någren K, Scheinin M, Hesse B, Juhani Airaksinen KE, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J.
    Circulation; 2008 Sep 16; 118(12):1250-8. PubMed ID: 18765391
    [Abstract] [Full Text] [Related]

  • 17. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
    Fragasso G, Salerno A, Lattuada G, Cuko A, Calori G, Scollo A, Ragogna F, Arioli F, Bassanelli G, Spoladore R, Luzi L, Margonato A, Perseghin G.
    Heart; 2011 Sep 16; 97(18):1495-500. PubMed ID: 21700755
    [Abstract] [Full Text] [Related]

  • 18. Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial.
    Ribeiro LW, Ribeiro JP, Stein R, Leitão C, Polanczyk CA.
    Am Heart J; 2007 Jul 16; 154(1):78.e1-7. PubMed ID: 17584555
    [Abstract] [Full Text] [Related]

  • 19. Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance.
    Leonardo F, Fragasso G, Rossetti E, Dabrowski P, Pagnotta P, Rosano GM, Chierchia SL.
    Cardiologia; 1999 Dec 16; 44(12):1065-9. PubMed ID: 10687257
    [Abstract] [Full Text] [Related]

  • 20. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
    Onay-Besikci A, Guner S, Arioglu E, Ozakca I, Ozcelikay AT, Altan VM.
    Can J Physiol Pharmacol; 2007 May 16; 85(5):527-35. PubMed ID: 17632588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.